Hubei Biocause Pharmaceutical Co., Ltd.

Sümbol: 000627.SZ

SHZ

2.3

CNY

Turuhind täna

-19.6629
P/E suhe
0.1626
PEG suhe
11.27B
MRK Cap
0.05%
DIV tootlus

Hubei Biocause Pharmaceutical Co., Ltd. (000627-SZ) Finantsaruanded

Q: Mis on ettevõtte kasumimarginaal?

Ettevõtte kasumimarginaal on .

Download

Aastane Quarterly

Lineaarne Log

Diagrammil näete Hubei Biocause Pharmaceutical Co., Ltd. (000627.SZ) vaikimisi numbreid dünaamikates. Companys revenue näitab keskmist NaN M, mis on NaN % gowth. Kogu perioodi keskmine brutokasum on NaN M, mis on NaN %. Keskmine brutokasumi suhtarv on NaN %. Ettevõtte eelmise aasta tulemuse puhaskasv on NaN %, mis on võrdne NaN % % keskmiselt kogu ettevõtte ajaloo jooksul.,

Aastane Quarterly

10Y 20Y 30Y 40Y

Bilanss

Sukeldudes Hubei Biocause Pharmaceutical Co., Ltd. fiskaalkäiguteele, täheldame keskmist varade kasvu. See määr on huvitaval kombel , mis kajastab nii ettevõtte kõrg- kui ka madalseisusid. Kui võrrelda kvartalite lõikes, siis kohandub see näitaja . Kui vaadata tagasi möödunud aastale, siis on varade kogumuutus NaN. Aktsionäride väärtus, mida näitab aktsionäride kogu omakapital, on hinnatud NaN aruandlusvaluutas. Selle aspekti aastane muutus on NaN%.

common:word.in-mln USD Growth	2022	2020	2018	2016	2014	2012	2010	2008	2006	2004	2002	2000	1998	1996	1994
balance-sheet.row.cash-and-short-term-investments	29952	28391.8	26157.8	30248.8	15203.5	18317.5	15336.9	10953.2	61.6	58.9	124.3	152.8	74.1	72.9	95.1	306.7	111.3	73.5	26.9	16.8	55.5	73.7	247	104.9	74.6	96	104.9	113.5	13.9	13.9	13.6
balance-sheet.row.short-term-investments	1798.4	2082.5	2907.5	3391.6	2211.8	62842.7	4164.8	50767.4	418.6	0	0	0	0	0	0	16.1	3.2	1.3	0	0	0	1.4	0	0	0	0	12	0	13.5	13.5	13.5
balance-sheet.row.net-receivables	0	-28453.6	17772.1	15069.6	10639.8	45548.8	9204.3	7697.9	83.7	140.8	188.6	339.1	391	277	295.6	231	198.2	318.7	428	407.2	455.9	280.7	296.1	28.7	8.7	8	4.1	5.6	3.4	0.2	26
balance-sheet.row.inventory	4131.9	10504	10224.5	10716.2	3671.6	3820.5	569.4	438.5	136.1	140.4	133.9	134.4	150.2	194.2	273.9	259.2	200.4	156.1	135	128.6	125.8	129.8	90.7	70.6	75.6	66.7	16.1	30	18.4	5.3	1.4
balance-sheet.row.other-current-assets	0	45535.3	-3796	-4291.5	-3729.8	-17868.2	2283.9	645.2	57.7	53.8	-8.1	-98.7	-45.5	-33.6	-29.1	-26.9	0.1	-93.8	-146.6	-130.9	-169.3	0	-105.7	171.7	92.1	73.9	23.9	18.1	23.2	19	-12.8
balance-sheet.row.total-current-assets	50665.9	55977.6	50358.4	51743.1	25785	49818.6	27394.5	19734.9	339.2	394	438.7	527.6	569.9	510.5	635.5	770	510	454.5	443.3	421.7	467.9	484.2	528.1	375.9	251.1	244.7	149	167.2	58.9	38.3	28.2
balance-sheet.row.property-plant-equipment-net	1290.6	844.1	830.3	580.4	567.2	770.9	698.9	587.4	334.7	454.2	619.2	601.7	448.9	527	798.5	612.4	374.3	354.7	336.6	343.3	338.4	322.2	262.9	355.1	376.4	274.9	159.7	111.5	63	32.9	26.5
balance-sheet.row.goodwill	6192.5	6192.2	6192.2	6192.2	6186.3	6186.3	6186.3	6186.3	0	0	0	0	0	1.8	1.8	1.8	1.8	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.intangible-assets	283.2	299.3	269.7	190	109.4	213.4	519.9	549.1	490.4	503.9	363.5	374.7	382.8	410.6	363.6	316.5	261.9	257.6	179.6	186.8	189.1	184.4	123.5	105	109.3	16.4	16.8	16.3	10.8	3.8	3.9
balance-sheet.row.goodwill-and-intangible-assets	6475.7	6491.6	6461.9	6382.2	6295.7	6399.7	6706.2	6735.4	490.4	503.9	363.5	374.7	382.8	412.3	365.4	318.3	263.7	257.6	179.6	186.8	189.1	184.4	123.5	105	109.3	16.4	16.8	16.3	10.8	3.8	3.9
balance-sheet.row.long-term-investments	133897.1	129743.2	13020.4	12217.8	12396.1	12983.8	15056.2	8280.1	742	716.8	689.8	543.4	463.3	517.5	330.1	260.4	172.5	100.1	127	127.3	94	100.6	74.4	43.9	22.5	139.1	12	0	13.5	13.5	13.5
balance-sheet.row.tax-assets	2654	2280.3	1010.3	976.2	944.2	1189.4	39.5	69.8	69.3	30.5	45.7	17.3	18.7	8.9	9.1	7.6	4.7	-2.7	-127	-127.3	-94	-2.7	0	1.8	1.9	2.3	-12	0	-13.5	-13.5	-13.5
balance-sheet.row.other-non-current-assets	106952.5	93262	192222.6	167502.9	159285.8	107091.6	90521.3	82469.2	433.6	9.1	0	0	0	0	17.2	10.9	-0.7	3.2	128.4	129.5	95.6	1.7	0.2	4.6	9.4	5	44.3	35.9	1.7	3.1	1.4
balance-sheet.row.total-non-current-assets	251270	232621.1	213545.5	187659.6	179488.9	128435.4	113022.2	98141.8	2070.1	1714.5	1718.3	1537.1	1313.7	1465.8	1520.3	1209.6	814.6	712.9	644.6	659.6	623.1	606.2	461	510.4	519.5	437.8	220.8	163.8	75.5	39.8	31.8
balance-sheet.row.other-assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-assets	301935.9	288598.7	263904	239402.6	205273.9	178254	140416.7	117876.7	2409.2	2108.5	2157	2064.7	1883.6	1976.3	2155.7	1979.5	1324.5	1167.4	1087.9	1081.3	1091	1090.4	989.1	886.3	770.7	682.5	369.8	331	134.4	78.2	60.1
balance-sheet.row.account-payables	949	206.9	93.5	35	156.5	83.5	106.1	82.8	74.4	112.8	208.7	84.8	62.6	34.8	37.5	45	67.9	119.6	45.7	51	25.7	26.8	18.6	51.6	29.5	40.1	19	12.5	7.5	3.1	0
balance-sheet.row.short-term-debt	18248.1	21189.6	9425.8	4583.8	6179.8	4640	7732.3	1414	303.5	428.9	484.6	327.8	253.2	142.8	274.8	192.7	279.4	231.9	252.4	251.4	284.4	249.4	134.5	154.4	96.4	54.9	7.7	14.9	8.1	3.3	6
balance-sheet.row.tax-payables	78.5	85.1	142.5	65.4	223.8	338.4	19.2	53.3	2.1	3.7	-43.3	-48.5	-9.7	0.6	6.9	2.8	29.3	11.2	3.6	2.4	6.6	9.7	32	26.4	15.4	6.2	6.6	15.1	8.8	10.5	2.2
balance-sheet.row.long-term-debt-total	7170.8	6877.9	6203.6	2760.3	-69.4	110.5	40.5	360	42	0	0	23	123	123	225	160	30	30	0	0	0	0	0	9	14	14	58.4	56.8	24.4	2.7	5.8
Deferred Revenue Non Current	179576.7	241.8	154781.7	147076.1	69.4	10.9	15.3	16	17.6	19.4	0	0	0	0	0	-160	-30	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.deferred-tax-liabilities-non-current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
balance-sheet.row.other-current-liab	46	3347.4	258.5	52	69.4	21424.5	8957.1	2072	8.3	8.8	14.5	12.6	5.9	13.1	20.5	11.8	17.6	21.7	23.7	22.7	19.3	16.8	8.2	12.8	5.3	4.9	0.8	6.4	1.5	0.8	6.9
balance-sheet.row.total-non-current-liabilities	243840.1	229010	213369.4	196798.4	162486.6	125753.1	103441.9	93669.4	198.5	41.3	15.8	34.8	134.5	134.5	225	160.2	30	30	0	0	0	0	0	9	16.2	15.2	58.4	56.8	24.4	2.7	5.8
balance-sheet.row.other-liabilities	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.capital-lease-obligations	71.6	89.6	111.2	69.3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-liab	268302.2	253995.8	226429.3	204814.7	170920.5	152239.5	113711.8	97479.2	625.5	618.8	720.7	527.4	469.5	374.2	581.3	466.8	458.5	443.7	356.7	357.4	372.2	322.4	226.1	291.8	199	189.5	176.6	130.9	82	34.3	18.8
balance-sheet.row.preferred-stock	0	1085.9	0	763.7	595.2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.common-stock	4940.6	4940.6	4940.6	4940.6	4940.6	4940.6	4940.6	4259.2	1353.6	1353.6	1353.6	1353.6	1353.6	1353.6	676.8	676.8	594.8	594.8	594.8	594.8	594.8	594.8	517.2	278.9	232.4	129.1	103.2	103.2	40.5	40.5	40.5
balance-sheet.row.retained-earnings	5310	6508.5	6327.4	5909.4	5829	4247.5	3142.4	1922.7	184.6	-37	-171.9	-70.8	-82.7	19	104.6	58.6	106.1	13.1	-31.5	-37.4	-41.7	6.4	27.8	73.4	59.9	36.2	12	32.9	3.4	0	0.8
balance-sheet.row.accumulated-other-comprehensive-income-loss	0	-1085.9	236.6	-763.7	-595.2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.other-total-stockholders-equity	10339.4	9962.8	11048.6	10284.9	10453.5	9804	11254	7619.9	201.5	132.4	214.1	214.7	105.3	172.4	736.8	726.2	113.6	99.1	94.7	93.5	92.8	92.8	143.6	175.4	215.1	312.4	77.9	64	8.5	3.3	0
balance-sheet.row.total-stockholders-equity	20590.1	21412	22553.3	21134.9	21223.1	18992.1	19337	13801.8	1739.7	1449	1395.8	1497.5	1376.2	1545	1518.2	1461.6	814.5	707	658	650.9	645.9	694	688.7	527.7	507.4	477.7	193.2	200.1	52.4	43.9	41.3
balance-sheet.row.total-liabilities-and-stockholders-equity	301935.9	288598.7	263904	239402.6	205273.9	178254	140416.7	117876.7	2409.2	2108.5	2157	2064.7	1883.6	1976.3	2155.7	1979.5	1324.5	1167.4	1087.9	1081.3	1091	1090.4	989.1	886.3	770.7	682.5	369.8	331	134.4	78.2	60.1
balance-sheet.row.minority-interest	13043.7	13191	14921.3	13453	13130.4	7022.5	7367.8	6595.7	44	40.7	40.4	39.9	37.9	57	56.3	51.2	51.6	16.7	73.2	73	72.9	74.1	74.3	66.8	64.2	15.3	0	0	0	0	0
balance-sheet.row.total-equity	33633.8	34602.9	37474.7	34587.9	34353.5	26014.5	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
balance-sheet.row.total-liabilities-and-total-equity	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Investments	135695.6	131825.7	116261.7	119224.9	120538.2	75826.6	61072.9	59047.4	1160.6	716.8	689.8	543.4	463.3	517.5	330.1	244.3	169.3	98.7	127	127.3	94	99.2	74.4	43.9	22.5	139.1	24	0	27	27	27
balance-sheet.row.total-debt	25418.9	28067.5	9425.8	4583.8	6179.8	4640	7732.3	1414	303.5	428.9	484.6	327.8	253.2	142.8	274.8	192.7	279.4	231.9	252.4	251.4	284.4	249.4	134.5	154.4	96.4	54.9	7.7	14.9	8.1	3.3	6
balance-sheet.row.net-debt	-2734.7	1758.2	-13824.5	-22273.3	-6811.9	-13677.5	-3439.9	-9539.2	241.9	370	360.3	175	179.1	69.9	179.7	-97.9	171.4	159.7	225.5	234.6	228.9	177.1	-112.5	49.6	21.7	-41.1	-85.2	-98.7	7.7	2.9	5.9

Rahavoogude aruanne

Hubei Biocause Pharmaceutical Co., Ltd. finantsmaastikul on viimase perioodi jooksul toimunud märkimisväärne muutus vabas rahavoos, mis näitab NaN nihet. Ettevõte laiendas hiljuti oma aktsiakapitali, emiteerides NaN, mis tähistab NaN erinevust võrreldes eelmise aastaga. Ettevõtte investeerimistegevuse tulemusel kasutas ettevõte netosularaha, mis aruandlusvaluutas oli NaN. See on NaN nihkumine võrreldes eelmise aastaga. Samal perioodil registreeris ettevõte NaN, NaN, NaN, mis on olulised ettevõtte investeerimis-ja tagasimaksestrateegiate mõistmiseks. Ettevõtte finantseerimistegevuse tulemusel kasutas ettevõte netorahavahendeid NaN, kusjuures erinevus võrreldes eelmise aastaga oli NaN. Lisaks eraldas ettevõte NaN aktsionäridele dividendide maksmiseks. Samal ajal tegi ta muid finantsmanöövreid, millele viidatakse kui NaN, mis samuti mõjutasid oluliselt tema rahavooge sel perioodil. Need komponendid koos annavad tervikliku pildi ettevõtte finantsseisundist ja strateegilisest lähenemisest rahavoogude juhtimisele.

common:word.in-mln USD Growth	2021	2019	2017	2015	2013	2011	2009	2007	2005	2003	2001	1999
cash-flows.row.net-income	510.6	880.2	1117.9	2918.6	2377.3	2678.3	3108.8	250.5	84.1	-100.4	13.8	-107.2	29.1	55.3	17.1	101.6	53.1	8.1	4.9	-49	7.8	46.7	40.3	35.4	30.5
cash-flows.row.depreciation-and-amortization	147.3	133.9	63.7	79.2	1123.9	122.9	139.3	64.8	73.5	68.8	52.4	62.9	66.5	52.3	40.5	42	35.6	37.6	35.9	34.2	37.3	28.9	28.6	25.1	13.1
cash-flows.row.deferred-income-tax	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.stock-based-compensation	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.change-in-working-capital	16073.1	11933.5	30709.3	35361	-26789.8	5245.9	-6232.5	23.9	-78.9	116.7	78	51.7	149.3	-122.8	-96.1	27.3	51.8	-13.7	15	-22.3	-131.2	-41.5	-83.5	-23.6	-52.1
cash-flows.row.account-receivables	1642.4	-609.1	-279.5	1548.8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.inventory	-279.6	471.1	-188.3	177.6	120.5	-130.9	-302.4	1.7	-6.5	0.5	15.8	12.3	79.7	-14.7	-58.7	-44.4	-21	-6.4	-1.8	4	-37.2	-20.1	4.9	8.9	-29
cash-flows.row.account-payables	-1642.4	609.1	279.5	-1548.8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.other-working-capital	16352.6	11462.5	30897.6	35183.5	-26910.3	5376.7	-5930.1	22.2	-72.4	116.2	62.2	39.5	69.6	-108.1	-37.3	71.6	72.9	-7.3	16.8	-26.3	-94	-21.4	-88.4	-32.5	-23.1
cash-flows.row.other-non-cash-items	-9206.7	-8775.1	-10469.8	-9759.2	38269.9	-7615.5	642	-385.9	-200	45.4	-50.4	59.5	-20.2	-5.3	24.9	-52.3	-12.4	16.7	0.3	11.2	16.5	3.2	10	10	3.4
cash-flows.row.net-cash-provided-by-operating-activities	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.investments-in-property-plant-an-equipment	-135.1	-287.1	-308.4	-717.1	-274.7	-778.9	-3678.3	-40.8	-185.5	-143.8	-128.5	-149.4	-93.1	-261.7	-361.7	-64.8	-130.1	-24.5	-25.5	-21.5	-146.1	-31.5	-6.3	-99.2	-10.8
cash-flows.row.acquisitions-net	17	1.8	-3440.5	258.8	334.3	1.4	3.5	3.2	103.1	162.9	131	44.3	0	263.4	361.8	65.9	130.1	0	28.3	21.8	146.9	0.2	10.7	0	10.8
cash-flows.row.purchases-of-investments	-97626.8	-109755	-71494.6	-123082.8	-77372.7	-139091.6	-115403.5	-6.2	-230	-146.7	-60	-40	-120.1	-40	-189	-60	-55.6	-0.8	-39	-165.8	-184.7	-24.8	-20.2	0	-31.5
cash-flows.row.sales-maturities-of-investments	84126.1	94717.7	67783.5	88942.6	68035	129051.5	104526.6	182.1	464.4	89	130	170	0	17.8	92.7	43.2	26.7	0	15.6	175.7	129.6	1.1	12.2	29.9	12
cash-flows.row.other-investing-activites	-1996.2	-62.2	-222.2	-445.9	102.8	-47.8	17138.3	7.1	5.3	-143.8	-128.5	-149.4	207.6	-261.7	-361.7	-64.8	-130.1	0	-25.5	-21.5	-146.1	62	-6.3	0.5	-10.8
cash-flows.row.net-cash-used-for-investing-activites	-15615	-15384.8	-7682.2	-35044.3	-9175.3	-10865.4	2586.6	145.4	157.2	-182.4	-56	-124.4	-5.6	-282.2	-458	-80.4	-159	-25.3	-46.2	-11.3	-200.6	7	-9.9	-68.8	-30.3
cash-flows.row.debt-repayment	-11763.8	-7701.9	-854.1	-102.8	-288	-790	-447.5	-464.9	-573.5	-463.3	-294.8	-223.3	-594.8	-279.7	-413.2	-231.9	-255.8	-240.6	-235.4	-329.9	-345.9	-178.9	-59.8	-67.9	-17.2
cash-flows.row.common-stock-issued	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.common-stock-repurchased	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.dividends-paid	-699.4	-381.3	-634	-242.1	-311.6	-148	-117.1	-24.5	-30.6	-30.4	-28.7	-21.6	-37.3	-20	-52.4	-17.8	-12.3	-14.3	-15.5	-15	-16.1	-22.7	-15.1	-6.2	-58.7
cash-flows.row.other-financing-activites	23541	15703.9	1660.6	1470.2	1940.4	11597.1	11190.3	407	515.3	484.6	364.4	303.7	390.8	406.8	1119.6	247.4	344.2	241.6	202.4	364.9	457.5	299.4	119.6	74.8	114.5
cash-flows.row.net-cash-used-provided-by-financing-activities	11077.8	7620.6	172.6	1125.3	1340.8	10659.2	10625.7	-82.4	-88.8	-9.1	40.9	58.8	-241.3	107.2	654.1	-2.3	76.2	-13.3	-48.6	20	95.5	97.8	44.7	0.6	38.6
cash-flows.row.effect-of-forex-changes-on-cash	72	-15.2	-33.9	-1.4	1.6	-2.1	3.8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-0.1	0
cash-flows.row.net-change-in-cash	3059	-3606.9	13877.6	-5320.8	7148.4	223.2	10873.7	16.2	-52.8	-61.1	78.7	1.3	-22.2	-195.5	182.6	35.8	45.3	10	-38.7	-16.8	-174.7	142.2	30.2	-21.4	3.1
cash-flows.row.cash-at-end-of-period	26309.3	23250.3	26857.1	12979.5	18300.4	11152	10928.8	55.1	38.9	91.8	152.8	74.1	72.9	95.1	290.6	108	72.2	26.9	16.8	55.5	72.3	247	104.9	74.6	96
cash-flows.row.cash-at-beginning-of-period	23250.3	26857.1	12979.5	18300.4	11152	10928.8	55.1	38.9	91.8	152.8	74.1	72.9	95.1	290.6	108	72.2	26.9	16.8	55.5	72.3	247	104.9	74.6	96	92.9
cash-flows.row.operating-cash-flow	7524.2	4172.6	21421.1	28599.6	14981.3	431.6	-2342.3	-46.7	-121.3	130.5	93.8	66.9	224.6	-20.5	-13.5	118.6	128.2	48.7	56.1	-25.9	-69.6	37.3	-4.6	46.9	-5.2
cash-flows.row.capital-expenditure	-135.1	-287.1	-308.4	-717.1	-274.7	-778.9	-3678.3	-40.8	-185.5	-143.8	-128.5	-149.4	-93.1	-261.7	-361.7	-64.8	-130.1	-24.5	-25.5	-21.5	-146.1	-31.5	-6.3	-99.2	-10.8
cash-flows.row.free-cash-flow	7389.1	3885.5	21112.7	27882.5	14706.7	-347.4	-6020.6	-87.5	-306.8	-13.3	-34.7	-82.4	131.5	-282.2	-375.2	53.8	-1.9	24.1	30.5	-47.4	-215.8	5.8	-10.9	-52.3	-16

Kasumiaruande rida

Hubei Biocause Pharmaceutical Co., Ltd. tulud muutusid võrreldes eelmise perioodiga NaN%. 000627.SZ brutokasum on teatatud NaN. Ettevõtte tegevuskulud on NaN, mille muutus võrreldes eelmise aastaga on NaN%. Kulud amortisatsioonikulud on NaN, mis on NaN% muutus võrreldes eelmise aruandeperioodiga. Tegevuskulud on teatatud NaN, mis näitab NaN% muutust võrreldes eelmise aastaga. Müügi- ja turunduskulud on NaN, mis on NaN% muutus võrreldes eelmise aastaga. Hiljutistel numbritel põhinev EBITDA on NaN, mis tähendab NaN% kasvu võrreldes eelmise aastaga. Tegevustulu on NaN, mis näitab NaN% muutust võrreldes eelmise aastaga. Puhaskasumi muutus on NaN%. Eelmise aasta puhaskasum oli NaN.

common:word.in-mln USD Growth	2022	2020	2018	2016	2014	2012	2010	2008	2006	2004	2002	2000	1998	1996
income-statement-row.row.total-revenue	49725.8	49615.7	49583.2	43576	50192.1	30950.8	53405.6	16995.5	541.1	806.4	968	779.7	1133.8	1261.2	964.6	909.3	835.8	560.8	518.7	463	422.7	348.6	356	322	255.9	192.3	237.5	143.7	83.3
income-statement-row.row.cost-of-revenue	9829.6	8458.6	7311.6	3225.1	8172.6	2866.9	4036.6	1788.5	518	829.8	977.5	753.2	1111.8	1185.8	866.2	835.1	726.1	475.6	451.1	410.6	380.8	268.7	261.2	240.2	193	155.3	176.4	98.2	53.9
income-statement-row.row.gross-profit	39896.2	41157.1	42271.6	40350.8	42019.5	28083.9	49368.9	15207	23.1	-23.4	-9.6	26.5	22	75.3	98.4	74.2	109.7	85.1	67.7	52.5	41.8	79.9	94.9	81.8	62.8	37	61.2	45.6	29.3
income-statement-row.row.gross-profit-ratio	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
income-statement-row.row.research-development	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-general-administrative	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-and-marketing-expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-expenses	-48509.6	9825.5	9896.8	36146.5	30062.1	-24280.3	-23688.3	-6190.4	3.1	8.3	13.2	1.5	0.3	9.8	6	5	6	10.3	4.7	9.5	1.5	2.6	8.3	7.3	20.6	11.9	5.6	6.6	2
income-statement-row.row.operating-expenses	-48509.6	10159.5	10437.9	36774.7	30668.5	2614.7	26761	6911.4	79.6	70.9	73.6	63.9	80.2	67.9	52.8	59	55.4	45.9	49.3	50.8	83.4	57	45	36.6	36.2	13	10	10.3	6.8
income-statement-row.row.cost-and-expenses	-51566.7	18618.1	17749.5	39999.8	38841.1	5481.6	30797.6	8699.9	597.6	900.7	1051.1	817.1	1192	1253.7	919	894.1	781.4	521.5	500.4	461.3	464.2	325.6	306.1	276.7	229.2	168.3	186.3	108.5	60.7
income-statement-row.row.interest-income	0	0	0	0	0	0	16.1	0	2.3	2.6	1.5	2.2	3.7	1.8	2.7	14.7	4.2	3.9	0.5	3.2	0.2	1.7	5.2	1.5	0	0	0	0	0
income-statement-row.row.interest-expense	0	31200.6	423.8	170.5	101.3	0	0	0	24.5	30.6	30.4	28.7	21.6	25.8	23.3	32.1	21	16.1	14.3	13.9	15.5	10.7	8.5	8.3	-0.4	-0.6	0.3	1.4	0.3
income-statement-row.row.selling-and-marketing-expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.total-other-income-expensenet	-1868	-30964.1	-32573.9	-2432.1	-8419.3	-18306.3	-4428.3	-1585.5	390.9	203.2	-45.4	52.4	-58.5	23.6	13.6	-7.9	58.1	13.2	-14.4	0.5	-9.5	-9.1	-0.2	-3.1	6.1	12.8	6.6	10.1	6.2
income-statement-row.row.ebitda-ratio-caps	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-operating-expenses	-48509.6	9825.5	9896.8	36146.5	30062.1	-24280.3	-23688.3	-6190.4	3.1	8.3	13.2	1.5	0.3	9.8	6	5	6	10.3	4.7	9.5	1.5	2.6	8.3	7.3	20.6	11.9	5.6	6.6	2
income-statement-row.row.total-operating-expenses	-1868	-30964.1	-32573.9	-2432.1	-8419.3	-18306.3	-4428.3	-1585.5	390.9	203.2	-45.4	52.4	-58.5	23.6	13.6	-7.9	58.1	13.2	-14.4	0.5	-9.5	-9.1	-0.2	-3.1	6.1	12.8	6.6	10.1	6.2
income-statement-row.row.interest-expense	0	31200.6	423.8	170.5	101.3	0	0	0	24.5	30.6	30.4	28.7	21.6	25.8	23.3	32.1	21	16.1	14.3	13.9	15.5	10.7	8.5	8.3	-0.4	-0.6	0.3	1.4	0.3
income-statement-row.row.depreciation-and-amortization	1840.9	147.3	133.9	63.7	79.2	1123.9	122.9	139.3	64.8	73.5	68.8	52.4	62.9	66.5	52.3	40.5	42	35.6	37.6	35.9	34.2	37.3	28.9	28.6	25.1	13.1	-11.9	-13.4	-8.3
income-statement-row.row.ebitda-caps	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.operating-income	1216.3	31188.8	32917	3881.5	12052.8	2653.6	2727.4	3424.8	332.2	101.1	-141.1	14.9	-113.7	22.2	53.2	2.3	106.4	53.1	8.2	-1.7	-45.1	15.8	57.5	48.3	41.8	30.7	63.1	48.6	30.8
income-statement-row.row.income-before-tax	-1868	224.8	343.1	1449.5	3633.4	2636.4	2724.3	3432.6	334.4	109	-128.6	15	-116.7	31.1	59.2	7.3	112.4	57.9	8.4	5	-47.3	16.2	57.7	48.9	47.6	39.7	63.3	50.3	30.8
income-statement-row.row.income-tax-expense	-1216.3	-285.8	-537.1	331.6	714.9	259.1	46	323.7	83.9	24.8	-28.1	1.2	-9.5	2	3.9	-0.1	20.5	4.8	0.3	0.1	1.7	8.3	11	8.5	12.2	9.2	8.5	13.4	8
income-statement-row.row.net-income	-651.8	510.6	880.2	1117.9	2918.6	1326.5	1326.2	1778.7	247.3	83.8	-101	11.8	-101.7	28.3	55.8	-23.8	89.7	48.4	7.1	5.1	-48.1	5.3	37.2	34.2	31.3	30.2	54.8	36.9	22.8